Ionis Pharmaceuticals CEO Brett P. Monia sells $356,012 in shares
Ionis Pharmaceuticals CEO Brett P. Monia sold a total of 4,536 shares of the company's common stock, realizing approximately $356,012 through transactions under a Rule 10b5-1 trading plan. These sales occurred shortly after Monia exercised non-qualified stock options. The company recently reported strong first-quarter 2026 earnings, surpassing Wall Street expectations, and raised its full-year revenue guidance.
Ionis (NASDAQ: IONS) CEO sells 4,536 shares after option exercise
Ionis Pharmaceuticals CEO Brett P. Monia exercised stock options for 4,536 shares and subsequently sold them in open-market transactions on May 13-14, 2026. The sales were conducted under a pre-arranged Rule 10b5-1 Trading Plan adopted in December 2025, with weighted average prices around $78.01 and $78.68 per share. Following these transactions, Monia directly holds 242,662 shares of Ionis common stock.
T. Rowe Price holds 6.16M IONS shares (NYSE: IONS) — 3.7% stake
T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G/A, reporting beneficial ownership of 6,159,027 shares of Ionis Pharmaceuticals (IONS), which represents a 3.7% stake in the company. The filing indicates that T. Rowe Price has sole voting power over 6,140,820 shares and sole dispositive power over all 6,159,027 shares. Despite disclosing these ownership details, the filing includes a statement explicitly denying beneficial ownership for the securities referenced.
Pinnacle Associates Ltd. Reduces Stake in Ionis Pharmaceuticals, Inc. $IONS
Pinnacle Associates Ltd. reduced its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 4.1% in the fourth quarter, selling 19,783 shares but still retaining 461,968 shares valued at $36.5 million. The company reported a better-than-expected quarterly loss of $0.56 per share on revenues of $246 million, an 86.4% year-over-year increase. Despite the strong earnings, insider selling, including shares from the CEO and an EVP, has been noted, while analysts maintain a "Moderate Buy" consensus with a target price of $99.35.
Ionis Pharmaceuticals, Inc. - Common Stock (NQ: IONS
This article provides recent news headlines related to Ionis Pharmaceuticals (IONS), primarily from April 2021. Topics include market movements such as stocks hitting 52-week lows, biotech pulse updates, and specific company news like Ionis's distribution agreement expansion and Akcea workforce restructuring. The current stock price for Ionis is also listed.
Biogen posts mid-stage trial data for Alzheimer’s candidate developed with Ionis
This article mentions that Biogen has released mid-stage trial data for an Alzheimer's candidate medication. The drug was developed in collaboration with Ionis. The article will likely detail the results of these trials.
Number of shareholders of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS
The article provides a brief snapshot of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) within the TradingView platform. It primarily displays navigation and financial data links for the company, indicating where to find information such as financials, news, and technical analysis. The page is focused on providing market data and tools related to the stock.
Ionis partner Biogen announces topline results from phase 2 Celia study of diranersen
Ionis Pharmaceuticals' partner Biogen has announced topline results from the Phase 2 Celia study of diranersen. This news is relevant to investors tracking Ionis Pharmaceuticals (IONS), which focuses on developing medicines for serious diseases, including neurologic and cardiovascular conditions. The article also provides recent analyst ratings and financial data for Ionis.
Oppenheimer Maintains an “Outperform Rating” on Pharmaceuticals, Inc. (IONS)
Oppenheimer has maintained an "Outperform" rating on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and raised its price target to $111 from $104, following strong first-quarter 2026 results and updated guidance. The company reported growing demand for TRYNGOLZA, raised its full-year revenue guidance, and advanced its pipeline with FDA acceptance for priority review of olezarsen and zilganersen. CEO Brett Monia highlighted strong performance in both commercial and R&D sectors, anticipating future Phase 3 readouts and launches.
Analysts Are Betting On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) With A Big Upgrade This Week
The article discusses the recent upgrade of Ionis Pharmaceuticals (IONS) by analysts, signaling increased confidence in the company. This upgrade is likely based on positive developments or future prospects for the biotech firm. Investors will be interested in understanding the reasons behind this significant change in analyst sentiment.
Need To Know: Analysts Are Much More Bullish On Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Revenues
Analysts have significantly upgraded their near-term revenue forecasts for Ionis Pharmaceuticals (NASDAQ:IONS), increasing the 2026 revenue estimate to US$893m from US$811m. Despite this increased optimism, the revised forecast still reflects an expected 16% decline in sales from the past 12 months and a substantially slower revenue growth compared to the broader biotech industry. The article suggests that with the anticipated improvement in the sales pipeline and the company nearing break-even, it might be an opportune time for investors to re-evaluate Ionis Pharmaceuticals.
Ionis Pharmaceuticals (IONS) director sells 77,289 shares under 10b5-1 plan
Ionis Pharmaceuticals director Joseph Loscalzo sold 77,289 shares of common stock on May 4, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. The sales, at weighted average prices of $75.58 and $74.90, were funded by exercising non-qualified stock options. Following these transactions, Loscalzo still retains over 36,000 shares of Ionis stock.
Ionis Pharmaceuticals(IONS.US) Director Sells US$5.8 Million in Common Stock
Ionis Pharmaceuticals (IONS.US) Director, Alfred Swayze, has sold 130,000 shares of common stock, valued at approximately US$5.8 million. The transaction was executed at an average price of US$44.62 per share on May 3, according to a recent SEC filing. This sale reduced Swayze's direct holdings in the company to 45,980 shares.
Insider Sell: Joseph Loscalzo Sells 77,289 Shares of Ionis Pharm
Joseph Loscalzo, a Director at Ionis Pharmaceuticals Inc (IONS), sold 77,289 shares of the company on May 4, 2026. This transaction is part of a trend of insider selling at Ionis, with 94 insider sells and no buys over the past year. The stock, trading at $75.06, is considered significantly overvalued with a price-to-GF-Value ratio of 1.38 against its estimated GF Value of $54.27.
Ionis Pharmaceuticals director Joseph Loscalzo sells $5.8m stock
Ionis Pharmaceuticals director Joseph Loscalzo sold approximately $5.8 million worth of common stock on May 4, 2026, following the exercise of non-qualified stock options. These transactions were carried out under a Rule 10b5-1 trading plan and occurred after a significant 136% gain in the company's stock price over the past year. The sales reduced Mr. Loscalzo's direct holdings to 36,330 shares, while the company recently reported strong Q1 2026 earnings and raised its full-year revenue guidance.
Ionis (NASDAQ: IONS) director exercises 10,111 options and sells shares under 10b5-1 plan
Ionis Pharmaceuticals director Joseph Klein III exercised non-qualified stock options for 10,111 shares at $47.11 per share and subsequently sold all 10,111 shares in open-market transactions under a pre-arranged Rule 10b5-1 Trading Plan. The sales occurred at weighted-average prices of $73.3530 for 8,680 shares and $74.4474 for 1,431 shares, totaling approximately $743,238. Following these transactions, Klein directly holds 11,014 shares of Ionis common stock.
Form 144: Option exercises listed; Joseph Loscalzo sold shares (IONS)
A Form 144 filing for Ionis Pharmaceuticals (IONS) indicates proposed sales related to various option exercises and two insider dispositions by Joseph Loscalzo. The filing details multiple option-exercise issuances on different dates totaling specific share counts and records Loscalzo's sales of 832 shares for $66,833 on March 3, 2026, and 200 shares for $16,000 on March 4, 2026. This is a routine regulatory report, assessed as neutral in sentiment and impact.
Ionis Pharmaceuticals (NasdaqGS:IONS) Stock Forecast & Analyst Predictions
Ionis Pharmaceuticals is forecast for significant growth, with earnings expected to increase by 63.9% and revenue by 28.1% annually. Recent positive developments include an upward revision of 2026 earnings guidance, an earnings beat in Q1 2026, and several of its investigational RNA-targeted medicines receiving Priority Review and Breakthrough Therapy designations from the FDA for conditions like severe hypertriglyceridemia, Alexander disease, and chronic hepatitis B.
Ionis to host 2026 virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals, Inc. announced its 2026 virtual Annual Meeting of Stockholders will take place on Thursday, June 4, 2026, from 5:00 p.m. to 5:15 p.m. ET. Following the meeting, CEO Brett P. Monia will provide a general corporate update, which will also be accessible via webcast. Stockholders of record as of April 7, 2026, can participate in the meeting using a 16-digit control number from their proxy materials.
Ionis Pharmaceuticals, Inc. (IONS) Investor Outlook: A 33.82% Upside Potential Beckons in the Biotech Sector
Ionis Pharmaceuticals (IONS), a company with a $12.44 billion market cap pioneering RNA-targeted medicines, presents a potential 33.82% upside with an average analyst target price of $100.74, trading at $75.28. Despite a forward P/E of -121.44 and significant R&D costs, its robust pipeline, including Phase 3 candidates Olezarsen and Zilganerse, and strategic partnerships, make it an attractive long-term prospect for investors. Analysts show strong confidence with 19 buy ratings, reflecting optimism in its innovative approach to treating serious diseases.
Ionis Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript
This article provides the transcript of Ionis Pharmaceuticals Inc's participation at the Leerink Global Healthcare Conference on March 9, 2026. The company's CEO, Brett Monia, was hosted by senior analyst Monty Fruhar to discuss relevant topics. The content focuses on the discussion that took place during the conference.
Kornitzer Capital Management Inc. KS Buys Shares of 29,105 Ionis Pharmaceuticals, Inc. $IONS
Kornitzer Capital Management Inc. KS recently acquired 29,105 shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) during the fourth quarter, a stake valued at approximately $2.30 million. This comes as other institutional investors have significantly increased their positions, contributing to 93.86% institutional ownership. Analysts have a "Moderate Buy" rating with a consensus price target of $99.35, following the company's Q1 earnings beat, where revenue increased 86.4% year-over-year.
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Ionis Pharmaceuticals (NASDAQ:IONS) from a "strong sell" to a "hold" rating, contributing to the stock's overall "Moderate Buy" consensus among analysts with an average price target of $99.35. The upgrade comes after Ionis reported stronger-than-expected quarterly earnings, with EPS of ($0.56) against an estimated ($0.85) and revenue significantly up by 86.4% year-over-year. Insider trading data shows recent sales by company executives, while institutional investors have adjusted their holdings, with Fifth Third Bancorp and Hsbc Holdings PLC notably increasing their stakes.
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Ionis Pharmaceuticals (NASDAQ:IONS) reported strong first-quarter results, with revenues significantly exceeding analyst forecasts by 26% and statutory losses being much smaller than expected. Following these results, analysts have modestly upgraded their revenue and loss per share forecasts for 2026, though the consensus price target remains largely unchanged. Despite the upgrades, the company's estimated revenue decline of 17% for 2026 still performs substantially worse than the projected industry growth.
Research Alert: CFRA Raises Rating On Shares Of Ionis Pharmaceuticals, Inc. To Buy From Hold
CFRA has upgraded its rating on Ionis Pharmaceuticals, Inc. (IONS) shares from "Hold" to "Buy". This revision reflects a positive outlook on the company's stock by the CFRA analysts.
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced strong first-quarter results, surpassing analyst expectations with revenues of US$246m and smaller-than-forecast losses. Analysts have subsequently upgraded their revenue and loss per share forecasts for 2026, anticipating US$879.5m in revenue and a loss of US$3.87 per share. Despite these upgrades, the consensus price target remains unchanged, suggesting no significant long-term impact on the stock's valuation, and the company's revenue growth is expected to underperform the industry.
Vanguard Group Inc. Sells 41,271 Shares of Ionis Pharmaceuticals, Inc. $IONS
Vanguard Group Inc. reduced its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 0.3% in the fourth quarter, selling 41,271 shares and retaining 16.44 million shares valued at approximately $1.30 billion. Insider selling has also been notable, with the CEO and other insiders selling a significant number of shares recently. Despite this, Ionis Pharmaceuticals beat revenue and EPS estimates in its latest quarterly report and holds a consensus analyst rating of "Moderate Buy."
Ionis to present at upcoming investor conferences
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that its management will participate in several investor conferences in May and June 2026, including events hosted by Bank of America Securities, RBC Capital Markets, and Goldman Sachs. Live webcasts of these presentations will be available on the Investors & Media section of the Ionis website. The company, a pioneer in RNA-targeted medicines, focuses on developing treatments for serious diseases in neurology, cardiometabolic disease, and other high-need areas.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2026 Earnings Call Transcript
Ionis Pharmaceuticals reported strong Q1 2026 financial results, exceeding earnings expectations with an EPS of $-0.56 against an expected $-0.85. The company highlighted accelerating demand for Tryngolza and strong early trajectory for DAWNZERA, leading to an increased annual peak sales estimate for olezarsen to over $3 billion. Ionis also updated its 2026 financial guidance, projecting total revenue between $875 million and $900 million due to robust commercial and R&D revenue streams.
Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan
Ionis Pharmaceuticals EVP and Chief Business Officer, Joseph Baroldi, sold 1,626 shares of company common stock at a weighted average price of $71.7877 per share on April 28, 2026. This open-market transaction was conducted under a Rule 10b5-1 Trading Plan established on November 25, 2025. Following the sale, Baroldi directly holds 44,909 shares, with an additional 4,347 shares held indirectly by his spouse.
Narrow-Moat Ionis' Peak Sales Raised for Olezarsen; Positive Outlook as Late-Stage Assets Advance
Morningstar has raised its peak sales projections for Ionis' Olezarsen, attributing this positive outlook to the drug's advancing late-stage development and potential for label expansion. Ionis Pharmaceuticals, recognized as a leader in RNA-based therapies with a narrow moat rating, continues to expand its promising pipeline despite facing competition from other RNA technology firms and gene editing approaches. The company's strategic focus on its pipeline, including its blockbuster drug Spinraza, positions it for long-term growth.
Oppenheimer Adjusts Price Target on Ionis Pharmaceuticals to $110 From $104, Maintains Outperform Rating
Oppenheimer has increased its price target for Ionis Pharmaceuticals (IONS) to $110 from $104, while reiterating an Outperform rating on the stock. This adjustment reflects a continued positive outlook from the firm regarding Ionis Pharmaceuticals' future performance and potential. Meanwhile, RBC also lifted its price target for Ionis Pharmaceuticals to $100 from $95, maintaining an Outperform rating.
Oppenheimer raises Ionis Pharmaceuticals price target on guidance
Oppenheimer has increased its price target for Ionis Pharmaceuticals (NASDAQ:IONS) to $110 from $104, maintaining an Outperform rating, following the company's strong Q1 2026 results. Ionis raised its full-year 2026 revenue guidance to $875-$900 million, up from $800-$825 million, driven by product launches and collaboration revenue. The biotech firm also significantly increased its peak sales forecast for olezarsen in SHTG to over $3 billion in the United States.
Ionis Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Ionis Pharmaceuticals Inc. has released its earnings summary for the quarter that ended on March 31. The report, provided by Refinitiv, gives a brief overview of the company's financial performance.
Ionis Pharmaceuticals Releases Q1 2026 Financial Results
Ionis Pharmaceuticals (IONS) reported its Q1 2026 financial results, showing a narrower basic and diluted net loss per share of $0.56, significantly better than the estimated -$0.92. The company generated $246.0 million in revenue, an 87.0% year-over-year increase, and projected full-year revenue guidance between $875.0 million and $900.0 million. This performance highlights improved financials compared to Q1 2025.
IONIS PHARMACEUTICALS ($IONS) Releases Q1 2026 Earnings
IONIS PHARMACEUTICALS ($IONS) announced its Q1 2026 earnings, reporting -$0.30 per share, significantly beating analyst estimates of -$0.92. The company also surpassed revenue expectations, bringing in $246 million against an anticipated $199.54 million. The report also details extensive insider selling activity and varied institutional investor movements, alongside recent analyst ratings and price targets for the stock.
Ionis reports first quarter 2026 financial results and highlights progress on key programs
Ionis Pharmaceuticals reported strong first-quarter 2026 financial results, with total revenue increasing by 87% year-over-year, driven by commercial success of TRYNGOLZA and DAWNZERA, and substantial R&D revenue. The company increased its annual TRYNGOLZA peak net sales guidance to over $3 billion for severe hypertriglyceridemia (sHTG) and improved its 2026 financial outlook, anticipating two additional independent launches for olezarsen (sHTG) and zilganersen (Alexander disease). Ionis also highlighted progress in its partnered programs, including positive Phase 3 data for bepirovirsen in chronic hepatitis B and upcoming results for pelacarsen and eplontersen.
Emerging Sub-Segments Transforming the Tegsedi Market Landscape
The Tegsedi market is projected for significant growth through 2030, driven by personalized genetic medicines, home-based treatments, precision diagnostics, and investments in RNA therapeutics. Key trends include the growth of RNA-targeted therapies, self-administered treatments, and an increased focus on disease-modifying therapies. Ionis Pharmaceuticals Inc. is a leading company, with recent collaborations aiming to enhance access to Tegsedi, particularly for rare diseases.
Ionis Pharmaceuticals Q1 2026 earnings preview
This article provides an earnings preview for Ionis Pharmaceuticals' Q1 2026 results. Key areas of interest will include their revenue performance and any updates on their pipeline or strategic initiatives. Investors will be looking for insights into the company's financial health and future growth prospects.
Pictet Asset Management Holding SA Raises Stock Position in Ionis Pharmaceuticals, Inc. $IONS
Pictet Asset Management Holding SA increased its stake in Ionis Pharmaceuticals by 1.8% in Q4, now owning 1,418,491 shares valued at $112.48 million. Despite missing Q4 EPS estimates, Ionis Pharmaceuticals beat revenue expectations, although revenue was down 10.6% year-over-year with negative net margins. Analysts maintain a "Moderate Buy" rating with a consensus price target of $97.35, even as company insiders have sold a significant number of shares recently.
GSK wins FDA priority review for Ionis hep B drug (GSK:NYSE)
GSK announced that the U.S. Food and Drug Administration (FDA) granted priority review for its marketing application for bepirovirsen. This hepatitis B therapy was licensed from Ionis Pharmaceuticals. The New Drug Application seeks U.S. approval for the drug.
FDA speeds review of hepatitis B drug targeting a functional cure
Ionis Pharmaceuticals' partner GSK has announced that the U.S. FDA has accepted bepirovirsen for Priority Review and granted it Breakthrough Therapy Designation for chronic hepatitis B. This investigational antisense oligonucleotide aims to provide a functional cure for the disease, evidenced by positive results from Phase 3 B-Well trials. The PDUFA target action date is set for October 26, 2026, marking a significant step towards addressing a global health challenge affecting millions.
Ionis gains priority review for zilganersen for Alexander disease
Ionis Pharmaceuticals has received priority review designation from the FDA for its investigational drug, zilganersen, which is being developed to treat Alexander disease. This rare and fatal neurodegenerative disorder currently has no approved treatments. The FDA is expected to make a decision on zilganersen's application by December 27, 2026.
M&T Bank Corp Buys 82,500 Shares of Ionis Pharmaceuticals, Inc. $IONS
M&T Bank Corp significantly increased its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 1,372.7% in Q4 2025, purchasing an additional 82,500 shares to hold a total of 88,510 shares valued at $7.0 million. This increase in institutional ownership comes amidst heavy insider selling, with executives disposing of over $67 million worth of shares in the last 90 days. Despite the insider selling, Wall Street analysts maintain a "Moderate Buy" rating with a consensus price target of $97.35 for Ionis Pharmaceuticals.
Ionis Pharmaceuticals targets $750M revenue for 2025 with multiple launches underway
Ionis Pharmaceuticals is targeting $750 million in revenue for 2025, driven by upcoming drug launches and recent FDA approvals. The company anticipates reaching this revenue goal with the help of new therapies for conditions like familial chylomicronemia syndrome (FCS) and generalized myasthenia gravis (gMG). This ambitious target reflects Ionis's pipeline progress and market expansion strategies.
[ARS] IONIS PHARMACEUTICALS INC SEC Filing
This article reports on an ARS SEC filing by IONIS PHARMACEUTICALS INC (IONS) on April 23, 2026, which is categorized as having low impact and neutral sentiment. The filing is available as a PDF document on SEC EDGAR. The page also provides an overview of IONS stock data, rankings, and recent news and SEC filings related to the company.
Ionis Pharmaceuticals (NASDAQ: IONS) seeks approval for equity plan and ESPP changes at 2026 meeting
Ionis Pharmaceuticals (NASDAQ: IONS) will hold its virtual 2026 Annual Meeting on June 4, 2026, where stockholders will vote on several proposals, including the election of two directors, an advisory "say on pay" vote, and the ratification of Ernst & Young LLP as independent auditors. Key proposals also include amendments to the 2011 Equity Incentive Plan to add 9,500,000 shares and to the 2000 Employee Stock Purchase Plan to add 750,000 shares and remove its termination date, aiming to enhance employee incentives and talent retention. The company highlighted its strong financial performance in 2025 with $944 million in revenue and its transition into a fully integrated commercial-stage biotechnology company with successful product launches and a rich pipeline.
West Michigan Advisors LLC Takes Position in Ionis Pharmaceuticals, Inc. $IONS
West Michigan Advisors LLC has acquired a new stake of 38,413 shares, valued at approximately $3.04 million, in Ionis Pharmaceuticals (NASDAQ:IONS) during the fourth quarter. This move aligns with other institutional investors increasing their positions, bringing total institutional ownership to about 93.86%. While the company missed Q4 EPS estimates, revenue exceeded expectations, and analysts have recently raised price targets, indicating a "Moderate Buy" consensus.
Ionis Pharmaceuticals, Inc. $IONS Stock Holdings Lowered by Teacher Retirement System of Texas
The Teacher Retirement System of Texas reduced its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 10.8% in the fourth quarter, now holding 422,899 shares valued at $33.46 million. Despite institutional investors owning nearly 94% of the company, insiders have recently sold a significant number of shares. Ionis reported a Q4 EPS miss but revenue beat expectations, with the stock trading around $74 and analysts maintaining a "Moderate Buy" consensus with an average target price of $97.35.
Ionis Pharmaceuticals, Inc. $IONS Shares Acquired by China Universal Asset Management Co. Ltd.
China Universal Asset Management Co. Ltd. significantly increased its stake in Ionis Pharmaceuticals ($IONS) by 51.7% in Q4, acquiring an additional 14,455 shares. This increased their total holdings to 42,394 shares, valued at approximately $3.35 million. Despite this institutional buying, company insiders have sold a substantial 864,155 shares worth around $67.0 million in the past 90 days.
